Pfizer Targets Summer For COVID-19 Vaccine Human Trials; Potential Treatment Also In The Works. [The Motley Fool]
BioNTech SE - American Depositary Shares (BNTX)
Company Research
Source: The Motley Fool
WhenPfizer(NYSE:PFEBioNTechPfizer's collaboration with BioNTech could significantly accelerate the vaccine development timeline. In fact, if the vaccine passes regulatory and clinical muster, the companies are looking at a vaccine launch date before the close of 00. If you've been holding out on buying Pfizer shares, here's why now might be the time to invest in this stock.Image source: Getty Images.A diverse portfolio of treatment candidatesPfizer is currently evaluating an unnamed compound for the treatment of the novel coronavirus, with hopes to initiate phase studies, which are tested on humans, by fall, assuming pre-clinical studies pass muster. During a preliminary data review, researchers confirmed that this compound is an inhibitor of the SARS-CoV- C-like protease and also exhibits anti-viral properties against SARS-CoV-.While preclinical studies are needed for further confirmation, these findings mean that this compound could halt or terminate the novel coronavirus in its ea
Show less
Read more
Impact Snapshot
Event Time:
BNTX
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
BNTX alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
BNTX alerts
High impacting BioNTech SE - American Depositary Shares news events
Weekly update
A roundup of the hottest topics
BNTX
News
- BioNTech SE (NASDAQ: BNTX) is now covered by analysts at Berenberg Bank. They set a "buy" rating and a $130.00 price target on the stock.MarketBeat
- BioNTech SE (NASDAQ: BNTX) was upgraded by analysts at Evercore ISI from an "in-line" rating to an "outperform" rating. They now have a $125.00 price target on the stock, up previously from $110.00.MarketBeat
- BioNTech SE (NASDAQ: BNTX) had its "buy" rating re-affirmed by analysts at HC Wainwright. They now have a $150.00 price target on the stock.MarketBeat
- BioNTech SE (NASDAQ: BNTX) had its "buy" rating re-affirmed by analysts at Canaccord Genuity Group Inc.. They now have a $171.00 price target on the stock.MarketBeat
- BioNTech to Acquire Biotheus to Boost Oncology StrategyGlobeNewswire
BNTX
Earnings
- 11/4/24 - Beat
BNTX
Sec Filings
- 11/15/24 - Form 144
- 11/14/24 - Form 6-K
- 11/13/24 - Form 6-K
- BNTX's page on the SEC website